These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 12605622)

  • 1. Use of pharmacoeconomics in prescribing research. Part 1: costs--moving beyond the acquisition price for drugs.
    Robertson J; Lang D; Hill S
    J Clin Pharm Ther; 2003 Feb; 28(1):73-9. PubMed ID: 12605622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of pharmacoeconomics in prescribing research. Part 3: Cost-effectiveness analysis--a technique for decision-making at the margin.
    Lopert R; Lang DL; Hill SR
    J Clin Pharm Ther; 2003 Jun; 28(3):243-9. PubMed ID: 12795784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.
    Lipsy RJ
    Pharmacoeconomics; 1992 Apr; 1(4):265-81. PubMed ID: 10147017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of pharmacoeconomics to formulary management in a health system setting.
    Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
    Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making a case for employing a societal perspective in the evaluation of Medicaid prescription drug interventions.
    Roy S; Madhavan SS
    Pharmacoeconomics; 2008; 26(4):281-96. PubMed ID: 18370564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug utilisation studies as tools in health economics.
    Sacristán JA; Soto J
    Pharmacoeconomics; 1994 Apr; 5(4):299-312. PubMed ID: 10147239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common errors and controversies in pharmacoeconomic analyses.
    Byford S; Palmer S
    Pharmacoeconomics; 1998 Jun; 13(6):659-66. PubMed ID: 10179701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacoeconomics in contemporary medicine].
    Czech M
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():16-9. PubMed ID: 15524007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool?
    Brinsmead R; Hill S
    J Clin Pharm Ther; 2003 Aug; 28(4):339-46. PubMed ID: 12911687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Research on hospital drug cost control based on the perspective of pharmaceutical economy.
    Xiu Y; Jia L; Chen J; Cui W
    Pak J Pharm Sci; 2017 May; 30(3(Special)):1057-1062. PubMed ID: 28671081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaceutical economy and the economic assessment of drugs in France.
    le Pen C
    Soc Sci Med; 1997 Aug; 45(4):635-43. PubMed ID: 9226787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
    Hoomans T; Severens JL; van der Roer N; Delwel GO
    Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.
    Reeder CE
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S5-8. PubMed ID: 8846244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics and formulary decision making.
    Sanchez LA
    Pharmacoeconomics; 1996; 9 Suppl 1():16-25. PubMed ID: 10160112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of antibacterial treatment.
    Davey PG; Malek MM; Parker SE
    Pharmacoeconomics; 1992 Jun; 1(6):409-37. PubMed ID: 10147022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacoeconomics--survey and status].
    Pedersen KM
    Ugeskr Laeger; 2003 Apr; 165(16):1670-4. PubMed ID: 12756827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics of genetically engineered drugs.
    Jones-Grizzle AJ; Bootman JL
    Pharmacoeconomics; 1992 Jan; 1(1):45-53. PubMed ID: 10172057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.